Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

67 results about "Clotting factor" patented technology

Definition of clotting factor. : any of several plasma components (such as fibrinogen, prothrombin, thromboplastin, and factor VIII) that are involved in the clotting of blood. — called also coagulation factor.

Double-stranded ribonucleic acid for reducing expression of blood coagulation factor XI and modifier and application of double-stranded ribonucleic acid

The invention provides double-stranded ribonucleic acid for reducing blood coagulation factor XI expression and a modifier and application of the double-stranded ribonucleic acid. Cell experiment results show that the oligonucleotide duplex can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.
Owner:BEIJING YUEKANGKECHUANG PHARM TECH CO LTD +1

Methods of treating hemophilic arthropathy using chimeric clotting factors

ActiveUS12161696B2Peptide/protein ingredientsSkeletal disorderChimera ProteinHemophilic arthropathy
The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotting factor and an Fc region.
Owner:BIOVERATIV THERAPEUTICS INC

Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.
Owner:SUZHOU RIBO LIFE SCIENCE CO LTD

Process for preparing high-purity human blood coagulation factor IX from plasma

The invention provides a process for preparing a high-purity human blood coagulation factor IX from plasma. The process comprises the following steps: acquiring plasma; adding anion gel, adsorbing, and collecting an eluted protein solution; adding heparin sodium, filtering, ultra-filtering and dialyzing to obtain dialyzed protein liquid; adding an S / D solution; adding anion gel for secondary adsorption, and collecting eluted protein liquid II; performing filtration, ultrafiltration and dialysis, and collecting eluted protein liquid after dialysis; filtering is performed; carrying out affinity gel chromatography purification, collecting eluent, and carrying out ultrafiltration and dialysis; filtering, and adding a dialysate containing glycine for dialysis to obtain a human blood coagulation factor IX stock solution; adjusting the titer, and adding heparin sodium to obtain a diluted solution; pre-filtering the diluted liquid to obtain a semi-finished product of the human blood coagulation factor IX; sterilizing, filtering, sub-packaging, carrying out vacuum freeze drying, carrying out dry heat virus inactivation, inspecting and packaging. According to the invention, the production process is simplified, the cost is reduced, the activity of the finally obtained human blood coagulation factor IX is greater than 50IU / ml, and the specific activity is higher than 180IU / mg.
Owner:CHINA RESOURCES BOYA BIO-PHARM GRP CO LTD

Diagnostic marker for hepatocellular carcinoma and application thereof

The invention relates to the technical field of hepatocellular carcinoma diagnosis, and particularly discloses a hepatocellular carcinoma diagnostic marker and application thereof.The hepatocellular carcinoma diagnostic marker is FGA, the FGA gene encodes an alpha subunit of blood coagulation factor fibrinogen, the fibrinogen is a constituent part of blood clots, the FGA is applied to detection of hepatocellular carcinoma, and the FGA gene can be used for detecting hepatocellular carcinoma. According to the application, the FGA expression in hepatocellular carcinoma tissues is lower than that in para-carcinoma tissues, the FGA expression in the plasma of a hepatocellular carcinoma patient is higher than that in normal healthy people, the FGA expression of the hepatocellular carcinoma postoperative patient is obviously reduced, and meanwhile, when the result of AFP diagnosis on the hepatocellular carcinoma patient is negative, the probability that the FGA in the plasma diagnoses the hepatocellular carcinoma patient to be positive reaches 75%, and the FGA expression in the hepatocellular carcinoma postoperative patient is obviously reduced. Therefore, the plasma FGA can obviously improve the detection rate of the AFP negative hepatocellular carcinoma, and the diagnosis efficiency of the hepatocellular carcinoma is improved.
Owner:THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV

Methods of treating hemophilic arthropathy using chimeric clotting factors

PendingUS20250121036A1Peptide/protein ingredientsSkeletal disorderHemophilic ArthritisChimera Protein
The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotting factor and an Fc region.
Owner:BIOVERATIV THERAPEUTICS INC

Factor XIa inhibitors

ActiveCN115066417BOrganic chemistryBlood disorderDiseaseCoagulation factor XIa
A blood coagulation factor XIa inhibitor of formula I, a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof in preparing a medicament for preventing or treating thrombosis and embolism-related diseases.
Owner:SHANGHAI JINGXIN BIOLOGICAL MEDICAL +1

Oil seal liquid and application thereof in blood coagulation detection

The invention relates to oil seal liquid and application thereof in blood coagulation detection, and belongs to the technical field of blood coagulation detection. The oil seal liquid can form a uniform film when covering a plasma sample, the activity of thrombin is not affected while air is isolated, and in addition, the oil seal liquid is a biological inert formula, is easy to clean and does not generate adsorption or reaction with blood coagulation factors and reagents. Therefore, the oil seal liquid and the sample are incubated synchronously in the pre-warming stage, and errors caused by sample evaporation and temperature fluctuation in the pre-warming stage can be reduced. Compared with traditional paraffin oil, the oil seal liquid can effectively isolate air to avoid sample evaporation and reduce reagent interference, is easy to clean, provides reliable technical support for blood coagulation factor deficiency and precise identification of inhibitors, and is suitable for APTT correction experiments, PT correction experiments or clinical detection and application of lupus anticoagulant (LA).
Owner:SYSCAN BIOTECH(SUZHOU) CO LTD

Nucleic acid targeting coagulation factor xi and use thereof

PCT designated stageWO2025201156A1Organic active ingredientsGenetically modified cellsThrombusVenous Embolism
The present invention relates to the technical field of biology, and in particular to a nucleic acid targeting coagulation factor XI and a use thereof. The nucleic acid of the present invention can effectively reduce the level of coagulation factor XI and can effectively inhibit the formation of thrombi, thereby preventing and / or treating multiple diseases caused by thrombi, such as pulmonary embolism, venous embolism, deep venous embolism, myocardial infarction, and stroke.
Owner:SYNERK BIOPHARMACEUTICALS LTD

Inhibitors of fxia

PCT designated stageWO2026006882A1PeptidesBlood disorderCyclic peptideDisease
The present disclosure describes cyclic peptide inhibitors of Factor XI (FXI), preferably FXIa. Also described are pharmaceutical compositions comprising the cyclic peptides and their use in treating conditions, diseases and / or disorders responsive to FXI, preferably FXIa inhibition, including thrombosis or thrombo-inflammatory conditions.
Owner:THE UNIV OF SYDNEY

A cold sediment automatic post-processing instrument and a preparation method of cold sediment blood coagulation factors

The application discloses a cold deposit full-automatic post-processing instrument and a preparation method of cold deposit blood clotting factors. The cold deposit full-automatic post-processing instrument comprises a separation system, the separation system comprises a squeezing disc and a weighing disc, and the squeezing disc is provided with a squeezing cavity; a transportation tensioning system can transport the first blood bag to the squeezing cavity, transport the second blood bag to the weighing disc, cut the pipeline of the double-pipe and tighten the double-pipe; a heat sealing system can heat seal the first heat sealing point, the second heat sealing point, the third heat sealing point and the fourth heat sealing point on the tightened double-pipe; a material head removing system, the transportation tensioning system can transport the double blood bag after heat sealing to the material head removing system to remove the Y-shaped material head; and a collection system comprising a first collection box and a second collection box. The application can improve the heat sealing efficiency of the blood bag, improve the working environment and shorten the exposure time of the plasma at room temperature.
Owner:长沙血液中心

Recombinant amebocyte clotting factors and uses thereof

Provided are recombinant amebocyte clotting factors, their formulation and use in determining the presence and / or amount of a microbial endotoxin in a sample. Also provided is a cartridge containing the recombinant amebocyte clotting factors for determining the presence and / or amount of a microbial endotoxin in a sample.
Owner:CHARLES RIVER LABORATORIES INC

Factor VIII deficiency plasma protectants and their applications

ActiveCN116425822BFactor VIII deficiencyAssay
This invention relates to the field of in vitro diagnostic reagent technology, specifically to a factor VIII deficiency plasma protectant and its application. The invention provides a protectant comprising a buffer, a lyophilization protectant, and a preservative, including factor VIII deficiency plasma and the protectant, and the application of factor VIII deficiency plasma in the preparation of coagulation factor activity assay reagents or kits. Compared with existing technologies, the protectant provided by this invention can effectively ensure the stability and activity of proteins in factor VIII deficiency plasma, further improving the performance of products containing factor VIII deficiency plasma, and resulting in higher precision of the prepared factor VIII deficiency plasma. The factor VIII deficiency plasma provided by this invention is suitable for most commercially available fully automated coagulation analyzers.
Owner:SHANGHAI SUNBIO TECH

Procoagulant Antibodies

The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.
Owner:NOVO NORDISK AS

A method for extracting and separating IgM and coagulation factor VII from plasma

The present invention relates to the technical field of blood product production, and specifically relates to a method for extracting and separating IgM and coagulation factor VII from plasma. The method comprises the following steps: after the cold glue plasma is adjusted in pH value and conductivity, it is loaded onto a first anion exchange chromatography column, and then sequentially eluted with a first eluent and a second eluent to obtain a first ion chromatography product; after the first ion chromatography product is ultrafiltered, dialyzed, and adjusted in pH value and conductivity, it is loaded onto a gel filtration chromatography column, and the flow-through solution corresponding to the first ultraviolet peak and the flow-through solution corresponding to the third ultraviolet peak are respectively collected to obtain a first gel filtration chromatography product containing IgM and a second gel filtration chromatography product containing coagulation factor VII. This technical solution can solve the technical problem that the existing preparation process cannot simultaneously purify and enrich IgM and human coagulation factor VII, and at the same time ensure the product quality, improve the utilization rate of plasma raw materials, and has ideal practical application value.
Owner:HUALAN BIOLOGICAL ENG CHONGQING

Compound with high inhibitory activity on blood coagulation factor XIIa as well as pharmaceutical composition and application of compound

The invention discloses a compound with high inhibitory activity on blood coagulation factor XIIa as well as a pharmaceutical composition and application of the compound. The structural formula of the compound is shown as a general formula (I) or (II). The benzo-seven-membered ring is adopted as a core structure, the benzo-seven-membered ring can well occupy an S1 pocket of the blood coagulation factor XIIa due to the large size and space flexibility, the affinity of molecules and a target spot is remarkably improved, and therefore the inhibition activity, selectivity and in-vitro anticoagulation and anti-inflammatory activity of the blood coagulation factor XIIa are improved, and the compound has good application prospects on the basis of avoiding or reducing the bleeding risk. The pharmaceutical composition is used for preventing and treating thrombus inflammation diseases, such as sepsis and atherosclerosis.
Owner:HEFEI UNIV OF TECH +1

Highly potent ISVD compounds capable of substituting for fviii(a)

The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
Owner:NOVO NORDISK AS

Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use

ActiveZA202108205B
Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.
Owner:SUZHOU RIBO LIFE SCIENCE CO LTD

Method and kit for monitoring anticoagulant therapy

ActiveUS12681025B2Test sampleFactor ii
A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.
Owner:FIIX DIAGNOSTICS

Therapeutic strategies to reduce thrombotic risk in factor v leiden (FVL) carriers

PCT designated stageWO2026039728A1Immunoglobulins against blood coagulation factorsOrganic active ingredientsThrombusVenous thromboembolism
Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.
Owner:REGENERON PHARMACEUTICALS INC

Modified Factor IX and Compositions, Methods and Uses for Gene Transfer into Cells, Organs and Tissues

To provide nucleic acid sequences, expression vectors (e.g., vector genomes) and plasmids, compositions and viral vectors in which the nucleic acid encodes Factor IX (e.g. human Factor IX).SOLUTION: A nucleic acid sequence encodes human Factor IX protein, where the nucleic acid has a reduced number of CpG di-nucleotides compared to a wild-type sequence encoding human Factor IX.SELECTED DRAWING: None
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA

Bispecific factor viii mimetic antibodies

The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and / or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and / or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A with or without inhibitors.
Owner:NOVO NORDISK AS

Factor xii binding peptides and methods of use

PCT designated stage expiredWO2025006536A2Peptide/protein ingredientsBlood disorderDiseaseBinding peptide
Disclosed herein, are peptides that bind coagulation factor XII (FXII). Also described herein, are methods of administering compounds comprising peptides that bind coagulation FXII to subjects for the treatment of cancer-associated thrombosis, sickle cell disease associated with vaso-occlusive crisis or vascular thrombosis, colon cancer, glioblastoma multiforme, organ fibrosis, Alzheimer's disease, and autoimmune encephalitis.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1

Detection of B Cell Antibody Responses in Patients with Haemophilia and Treatment Thereof

Embodiments of this disclosure include in vitro tests to detect clotting factor-specific antibodies produced by B cells from peripheral blood mononuclear cells (PBMCs) in patients with haemophilia that develop resistance to substitution therapy. Additional embodiments include therapeutic methods for treating patients with haemophilia who have been identified at risk of developing B cell mediated resistance to clotting factor-reconstitution (or substitution) therapy, or have developed resistance to such therapy, by selectively inactivating the B cells that produce clotting factor-specific antibodies, and monitoring the efficiency of the latter treatment by measuring the residual clotting factor-specific B cells in these subjects.
Owner:CELLULAR TECH LTD

A method for separating factor VIII from factor VWF in blood plasma

PendingCN122071517AFactor VIIPeptide preparation methodsCelluloseBlood coagulation factor VIII
The present application belongs to the technical field of blood product preparation, and particularly relates to a method for separating blood coagulation factor VIII and vWF factor from blood plasma. The method comprises the following steps in sequence: after cellulose is balanced, the cellulose is mixed with raw material blood plasma, filtered after stirring, and cellulose precipitate is obtained; after the cellulose precipitate is eluted, the cellulose precipitate is soaked in precipitate dissolving solution, and filtrate is obtained by filtering; the filtrate is subjected to three times of ion exchange chromatography, and factor VIII and / or vWF factor product is obtained. The technical scheme solves the technical problems of the prior art, such as complicated process steps for purifying and enriching human blood coagulation factor VIII and vWF from blood plasma cold precipitate, and unsatisfactory production efficiency and product quality. The cold precipitate protein solution prepared by the method can separate factor VIII, vWF factor and fibrinogen product at the same time through chromatography, improve the utilization rate of plasma protein, and has an ideal application prospect.
Owner:HUALAN BIOLOGICAL ENG CHONGQING

Glycosaminoglycan and / or series derivatives thereof as well as preparation method and application of glycosaminoglycan and / or series derivatives thereof

The invention relates to the field of natural product chemistry, sugar chemistry and biological medicine, and particularly provides glycosaminoglycan and / or a series of derivatives thereof as well as a preparation method and application of the glycosaminoglycan and / or the series of derivatives thereof, the glycosaminoglycan is extracted from starfish glabrata, and the preparation method comprises the following steps: extracting by adopting a papain combined alkaline hydrolysis method; the invention discloses an ALHX-2M series derivative and application of the ALHX-2M series derivative in prevention or treatment of thrombotic diseases, and the ALHX-2M series derivative is obtained by performing separation and purification through ion exchange column chromatography and molecular exclusion column chromatography to obtain ALHX-2M, and further performing deacetylation, deamination and depolymerization treatment and gel column chromatography separation and purification on the ALHX-2M series derivative and the application of the ALHX-2M series derivative in prevention or treatment of thrombotic diseases. The glycosaminoglycan and the derivative thereof take an endogenous blood coagulation factor X enzyme complex (FXase) as an action target, the anticoagulation activity and the antithrombotic activity of the glycosaminoglycan and the derivative thereof are superior to those of low-molecular-weight heparin, the bleeding risk under the equivalent antithrombotic dosage is remarkably reduced, and the glycosaminoglycan and the derivative thereof can be used for medicines or functional foods for preventing and treating thrombotic cardiovascular and cerebrovascular diseases.
Owner:GUANGXI UNIV OF CHINESE MEDICINE

Pharmaceutical composition comprising the extract of euphorbia hypericifolia as an effective component for prevention or treatment of thrombosis and health functional food comprising the same

PendingKR1020260140086ARed blood cellFood sector
The present invention relates to a pharmaceutical composition and a health functional food for the prevention or treatment of thrombosis containing an extract of Euphorbia hypericifolia, and more specifically, to a pharmaceutical composition and a health functional food for the prevention or treatment / improvement of thrombosis through inhibition of blood coagulation containing an extract of Euphorbia hypericifolia as an active ingredient having potent thrombin inhibitory and blood coagulation factor inhibitory activity. The extract of *Euphorbia hypericifolia*, used as an active ingredient in the pharmaceutical composition and health functional food for the prevention or treatment of thrombosis according to the present invention, exhibits excellent antithrombotic activity through strong inhibition of thrombus-related enzymes such as thrombin and blood coagulation factors. At the same time, it does not exhibit any hemolytic activity against human red blood cells, has excellent thermal stability, and does not show loss of blood coagulation factor inhibitory effects or thrombus-related enzyme inhibitory effects even under acidic conditions of pH 2 and in plasma. Therefore, it is expected to be usable for the prevention and treatment of thrombosis, such as ischemic stroke and hemorrhagic stroke, through the improvement of blood circulation. Furthermore, since the active ingredient has the excellent effect of being processed into various forms such as extract, powder, pills, and tablets, allowing for formulation into a form suitable for regular consumption, this invention is highly useful for the pharmaceutical and food industries.
Owner:GYEONGKUK NATIONAL UNIVERSITY IND -ACADEMIC COOP FOUNDATION

Coagulation-fibrinolysis high-balance type freeze-dried plasma as well as preparation method and application thereof

PendingCN119770631APowder deliveryPeptide/protein ingredientsVon Willebrand factorThrombus
The invention relates to the technical field of hemostatic preparations, in particular to blood coagulation-fibrinolysis high-balance type freeze-dried plasma as well as a preparation method and application of the blood coagulation-fibrinolysis high-balance type freeze-dried plasma. According to the blood coagulation-fibrinolysis high-balance type freeze-dried plasma provided by the invention, blood coagulation factors, anticoagulation factors, fibrinolysis factors, fibrinolysis inhibition factors and von willebrand factors with proper concentrations are compounded in the freeze-dried plasma according to different blood coagulation-fibrinolysis system change rules after different types of tissues and organs are damaged; the hemostatic resuscitation agent can be used for hemostatic resuscitation of general severe trauma, severe trauma mainly including liver, severe trauma mainly including severe craniocerebral trauma, severe trauma combined with seawater soaking and other injuries, the hemostatic resuscitation effect is good, thrombus of uninjured parts cannot be caused, and the lactic acid rising amplitude after trauma can be reduced.
Owner:ARMY MEDICAL UNIV